← Back to Patent Explorer
US4334016A Expired / Lapsed US ⏱️ 0.0 years remaining

Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test

Assignee: The Wistar Institute
•
Filing: 1980-06-19
•
Granted: 1982-06-08
•
Expires: 2000-06-19
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A human osteogenic sarcoma cell line chronically infected with human cytomegalovirus having a substantially constant ratio between immunofluorescent positive and noninfected cells useful in the immunofluorescent serological test for determining the presence of human cytomegalovirus antibody.

Inventors

  • 👤 Toru Furukawa

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-04 19:07
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/569; G01N33/56983; C; C12; C12N; C12N2510/00; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S435/968; Y10S436/00; Y10S436/80

Claims Analysis

Total Claims: 2
Claim 1
Independent Claim 140 words
A test procedure for determining the presence of human cytomegalovirus (HCMV) antibody in a sample of human blood which comprises substantially uniformly distributing on a surface as target cells a human osteogenic sarcoma cell line designated ATCC Accession Number CRL 8069 and characterized by an unlimited life span, by being chronically and persistently infected with HCMV, and by showing a substantially constant ratio between cells infected with HCMV and non-infected cells, the percentage of infected cells comprising from about 1 to about 10 percent of the total cells, inoculating said target cells with a diluted sample of blood serum to be tested for the presence of HCMV antibody, contacting the cells with a fluorescein isothiocyanate conjugated immunoglobulin, and optically viewing said cells to determine the presence of immunofluorescent positive cells resulting from reaction between cell antigens and test serum antibodies.
Claim 2
Dependent Claim 140 words
A test procedure for determining the presence of human cytomegalovirus (HCMV) antibody in a sample of human blood which comprises substantially uniformly distributing on a surface as target cells a human osteogenic sarcoma cell line designated ATCC Accession Number CRL 8069 and characterized by an unlimited life span, by being chronically and persistently infected with HCMV, and by showing a substantially constant ratio between cells infected with HCMV and non-infected cells, the percentage of infected cells comprising from about 1 to about 10 percent of the total cells, inoculating said target cells with a diluted sample of blood serum to be tested for the presence of HCMV antibody, contacting the cells with a fluorescein isothiocyanate conjugated immunoglobulin, and optically viewing said cells to determine the presence of immunofluorescent positive cells resulting from reaction between cell antigens and test serum antibodies.

References Cited (Backward Citations)

US4229532A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1985-06-07 1985-12-07 1986-06-08 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1989-06-07 1989-12-07 1990-06-08 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1993-06-07 1993-12-07 1994-06-08 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag